Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Book Value Per Share for the year ending December 31, 2023

Cyteir Therapeutics Inc Book Value Per Share is NA for the year ending December 31, 2023. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price.

Cyteir Therapeutics Inc Book Value Per Share for the year ending December 31, 2022 was 4.15, a -56.82% change year over year.
Cyteir Therapeutics Inc Book Value Per Share for the year ending December 31, 2021 was 9.61, a 577.75% change year over year.
Cyteir Therapeutics Inc Book Value Per Share for the year ending December 31, 2020 was -2.01, a -37.88% change year over year.
Cyteir Therapeutics Inc Book Value Per Share for the year ending December 31, 2019 was -1.46.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends